Home › Atherosclerosis › New Jersey
Atherosclerosis clinical trials in New Jersey
6 studies for Atherosclerosis are looking for participants at sites in New Jersey.
Cities in New Jersey
Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a)
- Clinical Research of Philadelphia, Pennington
- Cardio Metabolic Institute, Somerset
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 24, 2026 · NCT07157774Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
- CardioMetabolic Collaborative Clinic, Somerset
RecruitingPhase 3
Ages 45 to 99 · All sexes · Updated Sep 22, 2026 · NCT07037433Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)
- Hypertension & Nephrology Association, Eatontown
- New Jersey Kidney Care, Jersey City
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Sep 21, 2026 · NCT05485961A Phase III Study of AZD0780 on Major Adverse CV Events in Patients With a History of ASCVD Events or at High Risk for a First Event
- Research Site, Bridgewater
- Research Site, Elmer
- Research Site, Haddon Heights
- and 2 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Aug 24, 2026 · NCT07000357Lp(a) Lowering Study of Pelacarsen (TQJ230) With Background Inclisiran in Participants With Elevated Lp(a) and Established ASCVD
- Overlook Medical Center, Summit
RecruitingPhase 3
Ages 18 to 80 · All sexes · Updated Aug 7, 2026 · NCT06813911Pelacarsen Roll-over Extension Program
- Robert Wood Johnson Medical School, New Brunswick
- Overlook Medical Center, Summit
RecruitingPhase 3
Ages 18 to 100 · All sexes · Updated Jul 29, 2026 · NCT06875973From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.